PDS 0101

Drug Profile

PDS 0101

Alternative Names: PDS 101; PDS0101; PDS0101A; PDS0101B; Versamune-HPV

Latest Information Update: 12 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PDS Biotechnology Corporation
  • Class Cancer vaccines; Papillomavirus vaccines; Peptide vaccines
  • Mechanism of Action Cytokine stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cervical intraepithelial neoplasia

Most Recent Events

  • 10 Jul 2017 PDS Biotechnology enters into a clinical trial collaboration agreement with Merck for Head and neck cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater)
  • 10 Jul 2017 PDS Biotechnology and Merck plan a phase II trial for Head and neck cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater)
  • 13 Apr 2016 PDS Biotechnology completes a phase I trial in Cervical intraepithelial neoplasia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top